Atlas Trials

EpicentRx, Inc.

16 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch EpicentRx, Inc.

RecordFirmDate
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer (NCT05966194)EpicentRx, Inc.2024-04-02
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors (NCT04525014)EpicentRx, Inc.2023-01-26
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer (NCT05566041)EpicentRx, Inc.2022-08-01
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors (NCT04673942)EpicentRx, Inc.2021-03-29
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers (NCT03515538)EpicentRx, Inc.2018-07-12

Track EpicentRx, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.